(2) Salient Characteristics_W81K0223Q0129.pdf

PDF 48 KB Posted

Attached to
In-Vitro Diagnostic Reagents & Consumables for Ortho Vision Analyzer
Solicitation number
W81K0223Q0129
Issued by

About this file

This document outlines salient characteristics for in vitro diagnostic reagents and supplies for a federal contract opportunity. The opportunity seeks a contractor able to provide reagents and supplies compatible for use on an Ortho Clinical Diagnostics Vision Analyzer, including a minimum of three panels for antibody identification on bench and automated platforms. The contractor must be able to supply all reagents listed in the provided list, have a complete line of antigen typing antisera, and have manufacturer quality controls available for both automation and traditional bench testing. All products must be made in the USA, FDA approved, and the contractor must be able to provide 100% of the listed reagents. The related federal contract opportunity is solicitation number W81K0223Q0129 for in-vitro diagnostic reagents and consumables for the Ortho Vision Analyzer through the Department of the Army Medical Command.

View the file

Other files

File Type Posted
(3) Reagents List_W81K0223Q0129.pdf PDF
(1) Statement of Work_W81K0223Q0129.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

In Vitro (Traditional and Automated) Reagents/Supply Salient Characteristics

CHARACTERISTICS

(1) Must be compatible with use on Government owned analyzer (Ortho Clinical Diagnostics Vision Analyzer).

(2) All reagents must be made in the USA per FDA regulations/policy.

(3) Must be able to provide 100% of the reagents listed on the reagents list.

(4) Provide a minimum of 3 panels for antibody ID on bench and automated platform.

(5) Must have a complete line of antigen typing antisera (Kidd, Duffy, Rh, Lewis, MNSs).

(6) Manufacturer Quality Controls available for automation and bench testing.

(7) Must have capability to supply gel reagents and supplies and testing on gel automated platforms, gel back-up, AND traditional tube/bench testing.

(8) All reagents must be FDA approved.

File details come from the government source that posted it. Updated .